History Research Collection

Permanent URI for this collection

http://hdl.handle.net/10197/3501

For more information, please visit the official website.

Browse

Browsing History Research Collection by Type "Technical Report"

Now showing 1 - 2 of 2
  • Publication
    COVID-19 vaccines: in favour of a bespoke compensation scheme for adverse effects. A briefing paper
    (British Institute of International and Comparative Law, 2020-11-11)
    Fairgrieve, Duncan 
    ;
    Holm, Søren 
    ;
    Howells, Geraint 
    ;
    Kirchhelle, Claas 
    ;
    Vanderslott, Samantha 
    This is a briefing paper on behalf of a group of specialists drawn from different disciplines setting out the arguments in favour of a bespoke compensatory scheme for adverse effects to a COVID-19 vaccine(s). As set out below, it is our view that a no-fault compensation scheme could play a valuable role in relation to the acceptability of emergency COVID-19 vaccines.
      162
  • Publication
    Response to DHSC Open Consultation: Changes to Human Medicine Regulations to support the rollout of COVID-19 Vaccines
    (2020-09-18)
    Kirchhelle, Claas 
    We are writing in response to the UK Government consultation in respect of the proposals to modify the Human Medicine Regulations 2012 (“the Regulations”) in order to support the rollout of a COVID-19 vaccine. This is a submission to the consultation on behalf of a group of specialists drawn from different disciplines setting out our views on the proposed changes. Under the proposed modification of the Regulations, the envisaged scenario is that if there is a compelling case on public health grounds for using a vaccine before it is given a product licence, the Joint Committee on Vaccination and Immunisation may take the step of advising the UK government to use a tested, unlicensed vaccine/s against COVID-19. This would be a highly unusual step to take, and we have concerns about any UK Government decision to resort to the supply of an unlicensed medicinal product in this manner and the public health messaging that is thereby relayed. This is particularly the case in respect of one or several vaccines which have been developed under a fast-track procedure, potentially based on innovative technology, and which is to be used on such a wide scale to the general population.
      83